190 related articles for article (PubMed ID: 32172360)
1. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
[TBL] [Abstract][Full Text] [Related]
3. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
[TBL] [Abstract][Full Text] [Related]
4. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D
Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353
[TBL] [Abstract][Full Text] [Related]
5. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
[TBL] [Abstract][Full Text] [Related]
6. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis.
Russler-Germain DA; Cliff ERS; Bartlett NL
Blood; 2023 Dec; 142(25):2216-2219. PubMed ID: 37797275
[TBL] [Abstract][Full Text] [Related]
7. Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.
Assi R; Masri N; Dalle IA; El-Cheikh J; Ghanem H; Bazarbachi A
Clin Hematol Int; 2021 Mar; 3(1):21-26. PubMed ID: 34595463
[TBL] [Abstract][Full Text] [Related]
8. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE; Olszewski AJ; Assouline S; Lossos IS; Diefenbach C; Kamdar M; Ghosh N; Modi D; Sabry W; Naik S; Mehta A; Nakhoda SK; Smith SD; Dorritie K; Jia T; Pham S; Huw LY; Jing J; Wu H; Ead WS; To I; Batlevi CL; Wei MC; Chavez JC
Nat Med; 2024 Jan; 30(1):229-239. PubMed ID: 38072960
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
[No Abstract] [Full Text] [Related]
10. Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S; Hirata J; Musick L; Flowers CR
Am J Hematol; 2024 May; ():. PubMed ID: 38700035
[TBL] [Abstract][Full Text] [Related]
11. New agents and regimens for diffuse large B cell lymphoma.
Wang L; Li LR; Young KH
J Hematol Oncol; 2020 Dec; 13(1):175. PubMed ID: 33317571
[TBL] [Abstract][Full Text] [Related]
12. Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B; Chung E; Wellard C; Yoo E; Bennett R; Birks C; Johnston A; Cheah CY; Hamad N; Simpson J; Barraclough A; Ku M; Viiala N; Ratnasingam S; Armytage T; Cochrane T; Chong G; Lee D; Manos K; Keane C; Wallwork S; Opat S; Hawkes EA
EJHaem; 2024 Apr; 5(2):325-332. PubMed ID: 38633125
[TBL] [Abstract][Full Text] [Related]
13. Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Liao MZ; Deng R; Gibiansky L; Lu T; Agarwal P; Dere R; Lee C; Hirata J; Herbaux C; Salles G; Li C; Miles D
Clin Transl Sci; 2023 Dec; 16(12):2744-2755. PubMed ID: 37864313
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; ():. PubMed ID: 38622879
[TBL] [Abstract][Full Text] [Related]
15. Disseminated tuberculosis after Polatuzumab-Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma.
Elkourashy SA; Benkhadra M; Shafei L; Abujarir S; Ghasoub R
Clin Case Rep; 2024 May; 12(5):e8838. PubMed ID: 38721565
[TBL] [Abstract][Full Text] [Related]
16. Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma.
Corcoran SR; Phelan JD; Choi J; Shevchenko G; Fenner RE; Yu X; Scheich S; Hsiao T; Morris VM; Papachristou EK; Kishore K; D'Santos CS; Ji Y; Pittaluga S; Wright GW; Urlaub H; Pan KT; Oellerich T; Muppidi J; Hodson DJ; Staudt LM
Cancer Discov; 2024 Apr; ():. PubMed ID: 38683128
[TBL] [Abstract][Full Text] [Related]
17. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
Wang ML; Barrientos JC; Furman RR; Mei M; Barr PM; Choi MY; de Vos S; Kallam A; Patel K; Kipps TJ; Rule S; Flanders K; Jessen KA; Ren H; Riebling PC; Graham P; King L; Thurston AW; Sun M; Schmidt EM; Lannutti BJ; Johnson DM; Miller LL; Spurgeon SE
NEJM Evid; 2022 Jan; 1(1):EVIDoa2100001. PubMed ID: 38319241
[TBL] [Abstract][Full Text] [Related]
18. First Use of Upfront Polatuzumab Vedotin in Post-transplant Lymphoproliferative Disorder: A Case Report.
Paranji S; Steinberg A
Cureus; 2024 Mar; 16(3):e56409. PubMed ID: 38638728
[TBL] [Abstract][Full Text] [Related]
19. More than a lonca-shot: beating the odds in relapsed/ refractory diffuse large B-cell lymphoma.
Ho C; Smith SD
Haematologica; 2024 Apr; 109(4):1022-1024. PubMed ID: 37794796
[No Abstract] [Full Text] [Related]
20. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
Fowler N
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):277-283. PubMed ID: 27913492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
